GASTROINTESTINAL CANCER
Clinical trials for GASTROINTESTINAL CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL CANCER trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets tough cancers, but trial ends early
Disease control TerminatedThis early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…
Matched conditions: GASTROINTESTINAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New blood thinner tested for cancer Patients' clots – study halted early
Disease control TerminatedThis phase 3 trial tested a new drug, abelacimab, against a standard blood thinner (dalteparin) to prevent dangerous blood clots from returning in people with gastrointestinal or genitourinary cancers. The study enrolled 417 adults with advanced cancer and a recent clot. It was t…
Matched conditions: GASTROINTESTINAL CANCER
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Short nutrition boost before cancer surgery: does it help?
Disease control TerminatedThis study looked at whether giving well-nourished people with gastrointestinal cancer a special nutrition drink for 3 days before surgery could reduce complications and shorten hospital stays. The trial was stopped early, so results are limited. It involved 107 adults with stoma…
Matched conditions: GASTROINTESTINAL CANCER
Phase: NA • Sponsor: Société des Produits Nestlé (SPN) • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Cancer combo trial halted early: what we know
Disease control TerminatedThis phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…
Matched conditions: GASTROINTESTINAL CANCER
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC